4.18.23 | Policy
SWHR Statement on Ruling in Alliance for Hippocratic Medicine et al v FDA et al
SWHR issued a statement in anticipation of the Supreme Court ruling in response to the preliminary ruling of Judge Kacskmaryk of the U.S. District Court for the Northern District of Texas in the Alliance for Hippocratic Medicine et al v FDA et al case.
4.18.23
Exploring the State of Environmental Health and its Intersection with Women’s Health
Environmental health is a field of public health that focuses on the relationships between people and their environment to promote human health and well-being. As environments change so, too, do the impacts of environmental health.
4.14.23 | Policy
“Research Initiatives to Fortify the Health of Women in Populations with Health Disparities:” A Presentation by Dr. Webb Hooper
Monica Webb Hooper, PhD, Deputy Director of NIMHD addressed members of the SWHR Policy Advisory Council to discuss NIMHD’s research framework, work within women’s health, and how NIMHD is working to cultivate a diverse scientific workforce.
4.6.23 | HPV
Voicing Concern for the Rise in HPV-Associated Oral Cancers
Historically, oral cancer has been associated with smoking and alcohol consumption and diagnosed primarily in 60- and 70-year-old men. However, recently, HPV-associated oropharyngeal cancers increased by 1.3% in women each year.
3.31.23 | Autoimmune
Final Policy Brief of Four-Part Series Shines Light on Need for Diversity Within Autoimmune Clinical Trials
Recognizing the significant impact that diversity has on the nation's ability to improve autoimmune outcomes and advance health equity, SWHR developed the policy brief, “The Need for Diversity in Autoimmune Disease Research Trials.”
3.31.23 | Autoimmune
Third Policy Brief Highlights Role of Federal Agencies in Supporting Women with Autoimmune Diseases and Conditions
The SWHR policy brief, “Federal Agencies’ Work in Autoimmune Diseases and Conditions,” demonstrates how federal agencies are contributing to improved health and health care for women across the lifespan and why investments in these programs and initiatives should continue to be prioritized.
3.20.23
SWHR Announces 2023 Honoree in Industry in Advance of Annual Awards Gala
SWHR will recognize Horizon Therapeutics, a global biotechnology company, as the third health care leader honoree at its 2023 Annual Awards Gala on Wednesday, April 26, 2023.
3.14.23 | Endometriosis
SWHR Pushes for Endometriosis Awareness this March
Endometriosis is a chronic gynecological condition that affects approximately 6.5 million women of reproductive age in the United States, and it is especially common among people in their 30s and 40s.
3.14.23
SWHR Welcomes New Member to Board in 2023
SWHR is pleased to welcome Marianne Slight, Director of Product Management at Verily, as the newest member of its Board of Directors.
